metformin has been researched along with Libman-Sacks Disease in 16 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of metformin on insulin binding and insulin action in the presence of anti-insulin receptor antibodies was investigated in a case of type B extreme insulin resistance." | 7.68 | Metformin ameliorates extreme insulin resistance in a patient with anti-insulin receptor antibodies: description of insulin receptor and postreceptor effects in vivo and in vitro. ( Di Paolo, S, 1992) |
| " This research used in vivo and in vitro experiments to explore the therapeutic potential of metformin in kidney injury from LN-induced inflammation." | 4.12 | Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway. ( An, N; Chen, XC; Huang, LF; Huang, XR; Li, HY; Liu, HF; Liu, ZJ; Lu, X; Pan, QJ; Su, HY; Wu, D; Wu, HL; Yang, C; Zhu, SP, 2022) |
| "The effect of metformin on insulin binding and insulin action in the presence of anti-insulin receptor antibodies was investigated in a case of type B extreme insulin resistance." | 3.68 | Metformin ameliorates extreme insulin resistance in a patient with anti-insulin receptor antibodies: description of insulin receptor and postreceptor effects in vivo and in vitro. ( Di Paolo, S, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 8 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teng, X | 3 |
| Brown, J | 1 |
| Morel, L | 7 |
| Sun, F | 2 |
| Zhang, D | 1 |
| Wang, H | 5 |
| Liu, Z | 2 |
| Geng, S | 2 |
| Wang, X | 2 |
| Li, T | 3 |
| Wan, W | 2 |
| Lu, L | 2 |
| Ye, S | 3 |
| Chen, XC | 1 |
| Wu, D | 1 |
| Wu, HL | 1 |
| Li, HY | 1 |
| Yang, C | 1 |
| Su, HY | 1 |
| Liu, ZJ | 1 |
| Huang, XR | 1 |
| Lu, X | 1 |
| Huang, LF | 1 |
| Zhu, SP | 1 |
| Pan, QJ | 1 |
| An, N | 1 |
| Liu, HF | 1 |
| Jang, SG | 1 |
| Lee, J | 1 |
| Hong, SM | 1 |
| Kwok, SK | 1 |
| Cho, ML | 2 |
| Park, SH | 2 |
| Su, YJ | 1 |
| Wang, PW | 1 |
| Weng, SW | 1 |
| Moore, E | 1 |
| Reynolds, JA | 1 |
| Davidson, A | 1 |
| Gallucci, S | 1 |
| Rao, DA | 1 |
| Young, HA | 1 |
| Putterman, C | 1 |
| Wilson, CS | 1 |
| Stocks, BT | 1 |
| Hoopes, EM | 1 |
| Rhoads, JP | 1 |
| McNew, KL | 1 |
| Major, AS | 1 |
| Moore, DJ | 1 |
| Tan, MKX | 1 |
| Heng, TYJ | 1 |
| Mak, A | 1 |
| Titov, AA | 1 |
| Baker, HV | 1 |
| Brusko, TM | 2 |
| Sobel, ES | 2 |
| Kim, SC | 1 |
| Schneeweiss, S | 1 |
| Glynn, RJ | 1 |
| Doherty, M | 1 |
| Goldfine, AB | 1 |
| Solomon, DH | 1 |
| Yin, Y | 2 |
| Choi, SC | 2 |
| Xu, Z | 2 |
| Perry, DJ | 1 |
| Seay, H | 1 |
| Croker, BP | 2 |
| Chen, S | 1 |
| Gu, Y | 1 |
| Zeumer, L | 1 |
| Kanda, N | 1 |
| Lee, SY | 1 |
| Moon, SJ | 1 |
| Kim, EK | 1 |
| Seo, HB | 1 |
| Yang, EJ | 1 |
| Son, HJ | 1 |
| Kim, JK | 1 |
| Min, JK | 1 |
| Di Paolo, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus[NCT02741960] | Phase 4 | 180 participants (Actual) | Interventional | 2016-05-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for metformin and Libman-Sacks Disease
| Article | Year |
|---|---|
Redox Homeostasis Involvement in the Pharmacological Effects of Metformin in Systemic Lupus Erythematosus.
Topics: Animals; Homeostasis; Humans; Lupus Erythematosus, Systemic; Metformin; Mice; Neutrophils; Oxidation | 2022 |
Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis.
Topics: Humans; Lupus Erythematosus, Systemic; Metformin; Remission Induction; Severity of Illness Index; Ti | 2022 |
The Role of Mitochondria in Immune-Cell-Mediated Tissue Regeneration and Ageing.
Topics: Adaptive Immunity; Aging; Animals; Antigen-Presenting Cells; B-Lymphocyte Subsets; Cytokines; DNA; D | 2021 |
The Potential Use of Metformin, Dipyridamole, N-Acetylcysteine and Statins as Adjunctive Therapy for Systemic Lupus Erythematosus.
Topics: Acetylcysteine; Chemotherapy, Adjuvant; Dipyridamole; Drug Therapy, Combination; Humans; Lupus Eryth | 2019 |
2 trials available for metformin and Libman-Sacks Disease
| Article | Year |
|---|---|
Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials.
Topics: Adult; Double-Blind Method; Female; Humans; Lupus Erythematosus, Systemic; Male; Metformin; Middle A | 2020 |
Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Arthritis, Rheumatoid; Autoantibodies; Case-Control Stud | 2015 |
10 other studies available for metformin and Libman-Sacks Disease
| Article | Year |
|---|---|
Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway.
Topics: AMP-Activated Protein Kinases; Animals; Humans; Inflammation; Kidney; Lipopolysaccharides; Lupus Ery | 2022 |
Metformin enhances the immunomodulatory potential of adipose-derived mesenchymal stem cells through STAT1 in an animal model of lupus.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Immunomodulation; Lupus Erythematosus, Systemic; M | 2020 |
Promise and complexity of lupus mouse models.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Congresses as Topic; Disease Models, Animal; Drug | 2021 |
Metabolic preconditioning in CD4+ T cells restores inducible immune tolerance in lupus-prone mice.
Topics: Animals; Antibodies; Antimetabolites; CD4-Positive T-Lymphocytes; Deoxyglucose; Disease Models, Anim | 2021 |
Metformin Inhibits the Type 1 IFN Response in Human CD4
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Age | 2019 |
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2015 |
Normalization of CD4+ T cell metabolism reverses lupus.
Topics: Animals; CD4-Positive T-Lymphocytes; Deoxyglucose; Disease Models, Animal; Lupus Erythematosus, Syst | 2015 |
Glucose Oxidation Is Critical for CD4+ T Cell Activation in a Mouse Model of Systemic Lupus Erythematosus.
Topics: Animals; Autoimmunity; CD4-Positive T-Lymphocytes; Cells, Cultured; Deoxyglucose; Dichloroacetic Aci | 2016 |
Metformin Suppresses Systemic Autoimmunity in
Topics: AMP-Activated Protein Kinases; Animals; Autoimmunity; B-Lymphocytes; Blotting, Western; Cell Differe | 2017 |
Metformin ameliorates extreme insulin resistance in a patient with anti-insulin receptor antibodies: description of insulin receptor and postreceptor effects in vivo and in vitro.
Topics: Adipose Tissue; Autoantibodies; Erythrocytes; Female; Humans; Hydrogen-Ion Concentration; Insulin; I | 1992 |